Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study

Tamar Safra, Barliz Waissengrin, Deanna Gerber, Rinat Bernstein-Molho, Geula Klorin, Lina Salman, Dana Josephy, Rakefet Chen-Shtoyerman, Ilan Bruchim, Melissa K. Frey, Bhavana Pothuri, Franco Muggia

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objectives: We evaluated the incidence of breast cancer and overall survival in a multi-center cohort of ovarian cancer patients carrying BRCA1/2 mutations in order to assess risks and formulate optimal preventive interventions and/or surveillance. Methods: Medical records of 502 BRCA1/2 mutation carriers diagnosed with ovarian cancer between 2000 and 2018 at 7 medical centers in Israel and one in New York were retrospectively analyzed for breast cancer diagnosis. Data included demographics, type of BRCA mutations, surveillance methods, timing of breast cancer diagnosis, and family history of cancer. Results: The median age at diagnosis of ovarian cancer was 55.8 years (range, 23.9–90.1). A third (31.5%) had a family history of breast cancer and 17.1% of ovarian cancer. Most patients (67.3%) were Ashkenazi Jews, 72.9% were BRCA1 carriers. Breast cancer preceded ovarian cancer in 17.5% and was diagnosed after ovarian cancer in 6.2%; an additional 2.2% had a synchronous presentation. Median time to breast cancer diagnosis after ovarian cancer was 46.0 months (range, 11–168). Of those diagnosed with both breast cancer and ovarian cancer (n = 31), 83.9% and 16.1% harbored BRCA1 and BRCA2 mutations, respectively. No deaths from breast cancer were recorded. Overall survival did not differ statistically between patients with an ovarian cancer diagnosis only and those diagnosed with breast cancer after ovarian cancer. Conclusion: The low incidence of breast cancer after ovarian cancer in women carrying BRCA1/2 mutations suggests that routine breast surveillance, rather than risk-reducing surgical interventions, may be sufficient in ovarian cancer survivors.

Original languageEnglish
Pages (from-to)715-719
Number of pages5
JournalGynecologic Oncology
Issue number3
StatePublished - Sep 2021


  • BRCA1/2 mutation
  • Breast Cancer
  • Incidence
  • Ovarian Cancer
  • Surveillance


Dive into the research topics of 'Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study'. Together they form a unique fingerprint.

Cite this